Lacri-Lube
- Name:
Lacri-Lube
- Company:
Allergan Ltd
- Active Ingredients:
- Legal Category:
Supply through pharmacy only
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 26/09/18

XPIL
PACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER
1. What LACRI-LUBE is and what it is used for
1. What LACRI-LUBE is and what it is used for
2. Before You Use LACRI-LUBE
2. Before You Use LACRI-LUBE
3. How to use LACRI-LUBE
3. How to use LACRI-LUBE
4. Possible side effects
4. Possible side effects
5. How to store LACRI-LUBE
5. How to store LACRI-LUBE
6. FURTHER INFORMATION
6. FURTHER INFORMATION

Print ViewKeyword Search SmPC
1. NAME OF THE MEDICINAL PRODUCT
1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4. CLINICAL PARTICULARS
5. PHARMACOLOGICAL PROPERTIES
5. PHARMACOLOGICAL PROPERTIES
6. PHARMACEUTICAL PARTICULARS
6. PHARMACEUTICAL PARTICULARS
7. MARKETING AUTHORISATION HOLDER
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT
10. DATE OF REVISION OF THE TEXT
Allergan Ltd

Company Products
Medicine Name | Active Ingredients |
---|---|
Medicine Name Acular | Active Ingredients Ketorolac Trometamol |
Medicine Name Alphagan | Active Ingredients brimonidine tartrate |
Medicine Name Betagan | Active Ingredients Levobunolol hydrochloride |
Medicine Name Betagan Unit Dose | Active Ingredients Levobunolol hydrochloride |
Medicine Name BOTOX 100 Units | Active Ingredients Botulinum Toxin Type A |
Medicine Name BOTOX 200 Units | Active Ingredients Botulinum Toxin Type A |
Medicine Name BOTOX 50 Units | Active Ingredients Botulinum Toxin Type A |
Medicine Name Celluvisc 0.5% | Active Ingredients Carmellose sodium |
Medicine Name Celluvisc 1.0% w/v Eye drops, solution | Active Ingredients Carmellose sodium |
Medicine Name Combigan | Active Ingredients brimonidine tartrate, Timolol Maleate |
Medicine Name Exocin | Active Ingredients Ofloxacin |
Medicine Name FML | Active Ingredients Fluorometholone |
Medicine Name Ganfort | Active Ingredients Bimatoprost, Timolol Maleate |
Medicine Name Ganfort SD | Active Ingredients Bimatoprost, Timolol Maleate |
Medicine Name Lacri-Lube | Active Ingredients No Active Ingredients |
Medicine Name Liquifilm Tears | Active Ingredients Polyvinyl Alcohol |
Medicine Name Lumigan 0.1mg/ml | Active Ingredients Bimatoprost |
Medicine Name Ozurdex | Active Ingredients Dexamethasone |
Medicine Name Pred Forte | Active Ingredients Prednisolone Acetate |
Medicine Name Pred Mild | Active Ingredients Prednisolone Acetate |
Medicine Name Refresh Ophthalmic | Active Ingredients Polyvinyl Alcohol, Povidone |
Medicine Name Relestat 0.5 mg/ml, eye drops, solution | Active Ingredients Epinastine Hydrochloride |
Medicine Name Vistabel | Active Ingredients Botulinum Toxin Type A |
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 26 September 2018 PIL
Reasons for updating
- Change to section 5 - how to store or dispose
Updated on 18 December 2014 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Supply through pharmacy only
Updated on 18 December 2014 SmPC
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 17 December 2014 PIL
Reasons for updating
- New PIL for new product
Updated on 17 December 2014 PIL
Reasons for updating
- Change to side-effects
Updated on 22 May 2014 SmPC
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
The following wording have been added to the sec. 4.8 of the SPC:
(…)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.imb.ie
e-mail: imbpharmacovigilance@imb.ie
Updated on 9 May 2014 PIL
Reasons for updating
- Addition of information on reporting a side effect.
Updated on 6 September 2012 PIL
Reasons for updating
- Change to side-effects
- Correction of spelling/typing errors
Updated on 3 July 2012 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to improve clarity and readability
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated wording of 4.4 & 4.8 to harmonise across EU
Updated on 16 August 2010 PIL
Reasons for updating
- Correction of spelling/typing errors
Updated on 13 February 2009 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 13 February 2009 SmPC
Reasons for updating
- Correction of spelling/typing errors
Legal category: Supply through pharmacy only
Updated on 9 March 2007 SmPC
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 1 September 2006 SmPC
Reasons for updating
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 15 August 2005 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.5 - Nature and contents of container
- Change to section 7 - Marketing authorisation holder
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Updated on 27 June 2003 SmPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Supply through pharmacy only